The most common cause of hereditary colorectal (colon) cancer is Lynch Syndrome (“LS”). People with Lynch Syndrome have a 70% higher risk of developing colorectal cancer in their lifetime than the general population, and colorectal cancer is the leading cause of death among cancer cases in the U.S. Additionally, people with LS often develop colorectal cancer at much younger ages compared to the healthy population. However, there are no specific drugs that cure cancer, but following the set guidelines by the National Institute for Health and Care (“NICE”) in the UK, there may be some significant news. The information discussed below may offer a sigh of relief to the people suffering from colorectal cancer (“CRC”).
Clinical Trials by NICE
Recent clinical trials indicated that taking Aspirin for more than two years reduces the risk of colorectal cancer among people with Lynch Syndrome. In a clinical trial, only 4% of those who were taking daily Aspirin developed CRC as compared to the 7% under placebo group in a sample of 861 people with LS. However, adverse events did not vary significantly between the two groups. Furthermore, further studies…
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.